Glenmark Pharma receives USFDA approval for Estradiol Vaginal Insert
Glenmark Pharma has received final approval from the US health regulator for the generic version of Nordisk Inc's VAGIFEM, used for providing relief from menopause symptom.
New Delhi: Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Estradiol Vaginal.
Inserts USP, 10 mcg, the generic version of VAGIFEM®1, 10 mcg, of Novo Nordisk Inc.
According to IQVIATM sales data for the 12 month period ending July 2018, the VAGIFEM®, 10 mcg
market2 achieved annual sales of approximately $286.3 million. As of filing to BSE
Glenmark’s current portfolio consists of 139 products authorized for distribution in the U.S.
marketplace and 61 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings,
Glenmark continues to identify and explore external development partnerships to supplement and
accelerate the growth of its existing pipeline and portfolio.
ANDAEstradiol VaginalEstradiol Vaginal InsertGlenmark PharmamenopauseNordiskReliefUnited States Food & Drug AdministrationVAGIFEM
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd